COMP <GO>
QGEN vs ABBV // RSI-14 & 200D SMA MOMENTUM
Qiagen N.V. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: QGEN 6
— ABBV 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
rsi-technicals
71.9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 70.20% | -8.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 29.00% | -21.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 33.3x | -15.70 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 3.47% | +0.90 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 24.60% | -2.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 6.90% | +13.40 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.60% | -2.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 2.27% | -1.75 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.33 | -1.79 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | QGEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 71.9 | 72.8 | -0.85 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 113.1x | -90.40 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $513.86B | -$503.49B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | ABBV REV | QGEN GROSS % | ABBV GROSS % | QGEN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $61.16B | 62.2% | 70.2% | $453.3M | $17.82B |
| FY 2024 | $1.98B | $56.33B | 48.9% | 70.0% | $506.4M | $17.83B |
| FY 2023 | $1.97B | $54.32B | 44.0% | 44.0% | $371.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
ABBV // BETA 1.15